Uzm. Dr. Salih Karatlı

Doctor and researcher Ankara Etlik Şehir Hastanesi Ankara
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • Department name at the sourceOnkolojisaglik.gov.trFrom source
  • InstitutionAnkara Etlik Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 2 publications · Model version —From source
  • Publications32 publicationsORCID, OpenAlex, Europe PMCFrom source
  • ORCID0000-0002-4237-1606ORCIDFrom source
  • Last synchronised5 November 2026 07:23https://etliksehir.saglik.gov.tr/TR-864408/klinik-doktorlarimiz.html#salih-karatlisaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

32 publications

  1. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62040763 PMID 42075632 Open-access full textSource: ORCID

  2. Serum Vitamin D as a Predictor of Immunotherapy Response in Advanced Non-small Cell Lung Cancer

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-4-7 Open-access full textSource: OpenAlex

  3. Association Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab

    Medicina, 2026

    DOI 10.3390/medicina62081459 PMID 42654356 Open-access full textSource: OpenAlex

  4. Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors

    Expert review of anticancer therapy, 2026

    DOI 10.1080/14737140.2026.2733826 PMID 42733172 Source: Europe PMC

  5. Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072475 PMID 41976774 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  6. Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors

    Figshare, 2026

    DOI 10.6084/m9.figshare.33717648 Open-access full textSource: OpenAlex

  7. Prognostic Role of Nutritional and Inflammatory Indices in Predicting Adverse Clinical Outcomes in Unplanned Hospitalized Oncology Patients

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15082992 PMID 42074794 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  8. Prognostic value of pan-immune-inflammation index in hepatocellular carcinoma compared with albumin-bilirubin and model for end-stage liver disease sodium

    World Journal of Gastrointestinal Oncology, 2026

    DOI 10.4251/wjgo.121250 Open-access full textSource: OpenAlex

  9. Quality of Life and Psychological Factors in Patients with Metastatic Prostate Cancer Receiving Androgen Receptor–Targeted Therapies: A Prospective Cross-Sectional Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62061175 PMID 42356187 Open-access full textSource: OpenAlex

  10. Fear of Cancer Recurrence and Psychological Symptom Burden in Breast Cancer Survivors Without Evidence of Active Disease: A Cross-Sectional Real-World Study

    Healthcare (Basel, Switzerland), 2026

    DOI 10.3390/healthcare14162665 PMID 42651434 Open-access full textSource: Europe PMC

View all 32 publications